Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (often abbreviated as Pola-R-CHP) is a combination chemotherapy regimen used primarily for the treatment of previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), and high-grade B-cell lymphoma (HGBL). The regimen replaces vincristine in the traditional R-CHOP protocol with polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b on malignant B cells; it delivers monomethyl auristatin E (MMAE), a microtubule inhibitor, directly to these cells. Rituximab is a monoclonal antibody against CD20 on B lymphocytes. Cyclophosphamide and doxorubicin are cytotoxic chemotherapeutic agents with alkylating and anthracycline mechanisms respectively, while prednisone is a corticosteroid that exerts anti-inflammatory and immunosuppressive effects. This combination has been shown to improve outcomes in patients with moderate to high-risk DLBCL compared to standard regimens[1][3][5][7].
- Brand names
- PolivyRituxan
- Other names
- polatuzumab vedotin-piiq + rituximab + cyclophosphamide + doxorubicin hydrochloride + prednisonePola-R-CHP regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chainDNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone.